Tipsheet

'Big News' on the Coronavirus Vaccine Front

Cortney O'Brien
Cortney O'Brien  |  September 23, 2020 10:15 AM

Things are moving along nicely in the experimental vaccine department at Johnson & Johnson. The company has begun the final stage of clinical trials for its coronavirus contender. With 60,000 participants, it's the largest trial in the U.S. by far. The researchers say they should know by the end of the year whether they have a safe vaccine.

The vaccine candidate uses an adenovirus to carry a gene from the coronavirus into human cells. Then, it produces coronavirus proteins that can potentially prime the immune system to fight off a later infection by the virus, as the New York Times explains.

The president and his administration shared the "big news."

Johnson & Johnson's candidate has a few factors on its side. The vaccine contender does not need to be stored in subzero temperatures like the other two candidates offered by Moderna and Pfizer, and it may require just one dose instead of two.

Dr. Anthony Fauci has explained that, under Operation Warp Speed, they have about six or seven vaccine candidates in development. He too is "cautiously optimistic" that we'll have a safe and effective coronavirus vaccine by the end of 2020. Last week, Trump suggested that every American should expect to have access to a vaccine by April. 

Recommended

Joe Biden Just Lost Another Battle With His Teleprompter Spencer Brown
Why Is the Judge in Trump's New York Trial Muzzling a Key Defense Witness? Guy Benson

Wednesday's news from Johnson & Johnson should be welcome news for everyone. But, as Mark Levin recently noted, Trump critics have managed to even "denigrate" the impressive work of Operation Warp Speed. The president said it's because they think he'll get the "credit" for it.